Chapter 13 - Dose and therapy individualization in cancer chemotherapy
作者: Georg Hempel
作者单位: Westfälische Wilhelms-Universität Münster, Department of Pharmaceutical and Medical Chemistry, Clinical Pharmacy, Münster, Germany
出版社: Elsevier Inc.,   2020
ISBN: 978-0-444-64066-6
来源数据库: Elsevier Book
DOI: 10.1016/B978-0-444-64066-6.00013-7
关键词: Maximal tolerated doseNeutropeniaTherapeutic drug monitoringTyrosine kinase inhibitorVeno-occlusive disease
原始语种摘要: Anticancer drugs are good candidates for therapeutic drug monitoring (TDM) because of their high toxicity and documented exposure–response relationship for many anticancer drugs. In contrast to this, a few years ago Peterson concluded that in oncology “…plasma concentration monitoring has not proved to be of value to individualize the treatment…”. However, there are several examples where TDM in oncology has been shown to improve safety, and for some drugs, also efficacy. Examples such as 5-fluorouracil, busulfan, asparaginase, or imatinib are discussed below. It appears that there is a lack of interest of TDM and other pharmacokinetic issues in cancer chemotherapy. There is the perception that in case of toxicity or lack of efficacy switching to another drug is better than checking dose...
全文获取路径: Elsevier  (合作)

  • chemotherapy 化学疗法
  • cancer 癌症
  • asparaginase 天门冬酰胺酶
  • occlusive 闭合的
  • oncology 肿瘤学
  • efficacy 效验
  • therapeutic 治疗的
  • toxicity 毒性
  • concentration 浓度
  • monitoring 监视